Release date: 2024-08-15 17:58:48 Article From: Lucius Laos Recommended: 141
Selpercatinib is a targeted therapy drug that is mainly used to inhibit cancer caused by mutations in the RET gene. It has shown remarkable efficacy in controlling the spread of cancer cells and is suitable for the treatment of a variety of tumor types.
Selpercatinib has been approved for marketing in China, and the indications are not limited to cholangiocarcinoma and lymphoid tumors.
Treatment of patients 2 years of age and older, with RET gene fusion positive confirmed by an FDA-approved test, and patients with advanced or metastatic thyroid cancer who do not respond to radioactive iodine therapy.
Treatment for patients aged 2 years and older, with positive RET gene fusions confirmed by FDA-approved testing, progression after prior therapy, or no satisfactory alternative therapy.
When it comes to medication for special populations, patients should pay special attention to the following:
Patients with mild to severe renal insufficiency do not need to adjust the dose when using Selpercatinib. Doctors should monitor the patient's kidney function, paying attention to the effects of the drug on the individual.
Patients with mild to moderate hepatic impairment do not need to adjust the dose of Selpercatinib. Patients with severe hepatic impairment should reduce the dose. Doctors need to monitor these patients more frequently.
During the use of the drug, patients may experience the following adverse reactions:
The oral mucosa may be sore, red, swollen or painful, and in severe cases, it may interfere with eating and speaking. Patients may use non-alcoholic mouthwashes and local anesthetic medications to reduce oral discomfort, while spicy or acidic foods should be avoided.
Dry, uncomfortable eyes are common symptoms that can cause blurred or stinging vision. Patients can alleviate dry eye symptoms by using artificial tears or moisturizing eye drops, and an ophthalmologist should be consulted if necessary for further treatment.
[Warm tips] If you experience a rash, difficulty breathing, or other allergic symptoms after taking the drug, please stop the medication immediately and seek medical help. Follow your doctor's advice for regular follow-up appointments to monitor the effectiveness of your treatment and adjust the dosage as needed.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: